Humira, the injectable rheumatoid arthritis treatment is pictured in a pharmacy in Cambridge, Massachusetts on Wednesday, January 25, 2006. Abbott Laboratories said fourth-quarter sales were lifted by surging demand for its arthritis treatment while Bristol-Myers Squibb Co. said revenue fell as it faces a patent fight on its best-selling product. Photographer: JB Reed/Bloomberg News Credit: J.B. Reed/Bloomberg

Workers filled fewer prescriptions in 2023 than in 2022, and the drug that cost their employers the most was Humira — a drug that tries to keep people's immune systems from attacking their own cells — not the hot new GLP-1 agonist diabetes and obesity control drugs.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Allison Bell

Allison Bell, a senior reporter at ThinkAdvisor and BenefitsPRO, previously was an associate editor at National Underwriter Life & Health. She has a bachelor's degree in economics from Washington University in St. Louis and a master's degree in journalism from the Medill School of Journalism at Northwestern University. She can be reached through X at @Think_Allison.

Consumer Driven Health Care
Core and Group Health
Health Care Reform
Employer-Paid